Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 3/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151717 | 0.71 | PPARD (0.45) | CA1CA2CA9MAOBPPARD | |
| SCHEMBL14283334 | 0.70 | LTA4H (0.37) | SCN1ASCN5ASCN9AMAOBLTA4H | |
| SCHEMBL15862913 | 0.69 | PTGS2 (0.38) | KIF11 | |
| SCHEMBL377865 | 0.69 | PPARD (0.39) | CA1CA2CA9MAOBPPARD | |
| SCHEMBL2608846 | 0.69 | ALDH1A1 (0.49) | MAOBPPARDALDH1A1MAPT | |
| SCHEMBL227610 | 0.68 | CACNA1H (0.46) | CA1CA2CA9MAOBLTA4H | |
| SCHEMBL10994700 | 0.68 | SLC6A4 (0.40) | CA1CA2CA9PPARA | |
| SCHEMBL2349502 | 0.67 | ALDH1A1 (0.41) | ALDH1A1MMP9 | |
| SCHEMBL6937934 | 0.67 | CA1 (0.66) | CA1CA2CA9ALDH1A1KIF11 | |
| SCHEMBL5973845 | 0.66 | APP (0.46) | MAOBPPARDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-8450371-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2012-12-20 | — | — | US | disclosed |
| US-8258177-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
| US-8008513-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-30 | — | — | US | disclosed |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2010-01-07 | — | — | US | disclosed |
| US-7598292-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-06 | — | — | US | disclosed |
| EP-1670744-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACI DS AND ANALOGS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | CYMABAY THERAPEUTICS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005030694-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CA1 4761/4885CA2 2857/4885CA9 3800/4885 |
| US-20110294875-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CA1 4761/4885CA2 2857/4885CA9 3800/4885 |
| US-20100004470-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CA1 4761/4885CA2 2857/4885CA9 3800/4885 |
| US-20050107469-A1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | CA1 4761/4885CA2 2857/4885CA9 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.